Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.61% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. focuses on developing and commercializing innovative delivery systems for oncology. While specific founding dates and early milestones are limited in readily available public information, they've been progressing in targeted cancer therapeutics.
Core Business Areas
- Drug Delivery Systems: Development and commercialization of drug delivery systems targeting liver and pancreatic tumors.
- Immunotherapy: Enhancing the delivery and efficacy of immunotherapies directly to tumors.
Leadership and Structure
Information on the complete leadership team structure and members is limited in readily available public resources. Public data details the CEO and CFO roles. Further details would require deeper analysis of company filings.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: A pressure-enabled drug delivery system designed to enhance therapeutic penetration into solid tumors, particularly in the liver. Market share data is currently not readily available in standardized reports. Competitors include companies that offer regional cancer therapies or infusion devices.
- Match Trial Program: Trial of combination of TriNav with checkpoint inhibitor. Market share data is currently not readily available in standardized reports. Competitors include companies that offer regional cancer therapies or checkpoint inhibitor therapies.
Market Dynamics
Industry Overview
The oncology therapeutics market is rapidly growing, driven by increasing cancer incidence and advancements in targeted therapies and immunotherapies. Demand for improved drug delivery methods is increasing.
Positioning
TriSalus is positioned as an innovator in regional cancer therapies, focusing on improving drug delivery to solid tumors. They have a competitive advantage based on their pressure-enabled drug delivery technology.
Total Addressable Market (TAM)
The total addressable market for liver and pancreatic cancer therapeutics is multi-billion dollar. TriSalus is positioned to capture a significant share of this market with their targeted drug delivery systems. Specific TAM estimates depend on market segmentation and growth projections.
Upturn SWOT Analysis
Strengths
- Proprietary pressure-enabled drug delivery technology
- Focus on difficult-to-treat solid tumors
- Potential for improved therapeutic efficacy and reduced systemic toxicity
- Pipeline of drug delivery systems and combination therapies
Weaknesses
- Limited market presence and commercial infrastructure
- Reliance on clinical trial outcomes for product approval and adoption
- Competition from established pharmaceutical and medical device companies
- Relatively small company size
Opportunities
- Expanding clinical applications of drug delivery systems
- Partnering with pharmaceutical companies to develop combination therapies
- Securing regulatory approvals and reimbursement for products
- Acquiring or licensing complementary technologies
Threats
- Regulatory hurdles and delays
- Clinical trial failures
- Competition from alternative therapies
- Pricing pressures from healthcare payers
Competitors and Market Share
Key Competitors
- CRIS
- Varian Medical Systems (Siemens Healthineers)
- Boston Scientific (BSX)
Competitive Landscape
TriSalus has a competitive advantage in targeted drug delivery. However, larger companies have more market power and product ranges. They must continue to innovate and produce positive clinical results.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires access to specific quarterly and annual reports. Public information is limited.
Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption of their products. Analyst estimates are not readily available and are rapidly changing.
Recent Initiatives: Recent initiatives focus on advancing clinical trials of their drug delivery systems and exploring potential partnerships.
Summary
TriSalus Life Sciences Inc. is a small company pioneering targeted drug delivery in oncology. It has innovative technology but needs to demonstrate clinical efficacy and commercial success. Challenges include competition from larger players, regulatory hurdles, and the need for partnerships. The company's future depends on securing regulatory approvals and expanding the use of its drug delivery systems. They have a long way to go.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on limited public information and may not be comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.